The present invention relates to a novel compound, which enables additional hydrogen bonding with amino acids at specific positions of histone acetyltransferase (HAT) p300, through structure analysis of HAT p300. The novel compound of the present invention has a remarkably excellent effect of inhibiting HAT p300 activity and thus can be very effectively used in the prevention, alleviation, or treatment of fibrosis, which is a disease associated with activation of HAT p300.

The present invention relates to a novel compound, which enables additional hydrogen bonding with amino acids at specific positions of histone acetyltransferase (HAT) p300, through structure analysis of HAT p300. The novel compound of the present invention has a remarkably excellent effect of inhibiting HAT p300 activity and thus can be very effectively used in the prevention, alleviation, or treatment of fibrosis, which is a disease associated with activation of HAT p300.

The present invention relates to the treatment of disorders associated with oxidative stress including neuropathic pain and small synthetically derived compounds for treating such disorders.

A quinone derivative is represented by general formula (1), (2), or (3). In general formulae (1), (2), and (3), R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.21, R.sup.22, R.sup.23, and R.sup.24 each represent, independently of one another, a hydrogen atom, a cyano group, a halogen atom, an optionally substituted alkyl group having a carbon number of 1-6, or an optionally substituted alkoxy group having a carbon number of 1-6. R.sup.5, R.sup.6, R.sup.15, R.sup.16, R.sup.25, and R.sup.26 each represent, independently of one another, an optionally substituted alkyl group having a carbon number of 1-6, an optionally substituted alkoxy group having a carbon number of 1-6, an optionally substituted aryl group having a carbon number of 6-14, an optionally substituted aralkyl group having a carbon number of 7-12, or an optionally substituted cycloalkyl group having a carbon number of 3-10.

##STR00001##

A quinone derivative is represented by general formula (1), (2), or (3). In general formulae (1), (2), and (3), R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.21, R.sup.22, R.sup.23, and R.sup.24 each represent, independently of one another, a hydrogen atom, a cyano group, a halogen atom, an optionally substituted alkyl group having a carbon number of 1-6, or an optionally substituted alkoxy group having a carbon number of 1-6. R.sup.5, R.sup.6, R.sup.15, R.sup.16, R.sup.25, and R.sup.26 each represent, independently of one another, an optionally substituted alkyl group having a carbon number of 1-6, an optionally substituted alkoxy group having a carbon number of 1-6, an optionally substituted aryl group having a carbon number of 6-14, an optionally substituted aralkyl group having a carbon number of 7-12, or an optionally substituted cycloalkyl group having a carbon number of 3-10.

##STR00001##

Biomass derived benzoin derivatives, and methods of making and using the same, are described. Benzoin derivatives may be used as visible light photoinitiators.

Biomass derived benzoin derivatives, and methods of making and using the same, are described. Benzoin derivatives may be used as visible light photoinitiators.

Compositions and methods for treating thrombosis, inflammation, and atherosclerosis by administration of a compound that binds to KRIT1 to inhibit binding with HEG1.

Compositions and methods for treating thrombosis, inflammation, and atherosclerosis by administration of a compound that binds to KRIT1 to inhibit binding with HEG1.

A P-type dopant is provided, which is a planar aromatic compound having different numbers of fluorine atoms and cyano groups connected at a periphery thereof, and allows adjustment of highest occupied molecular orbital (HOMO) energy levels and lowest unoccupied molecular orbital (LUMO) energy levels and effectively increases luminous efficiency of a light emitting layer. Moreover, an organic light emitting diode is disclosed, including an anode, a cathode, and a light emitting structure located between the anode and the cathode, wherein a hole injecting layer of the light emitting structure is a hole injecting layer including the P-type dopant described above.